Aurobindo Pharma has launched Cefpirome, a fourth generation broad spectrum injectable cephalosporin, for the first time in the country and one of the few in the world.
Cefpirome is the first in the line of the latest cephalosporins group and it offers enormous advantages in anti-bacterial treatment, especially in life-threatening infections.
Aurobindo will market the product under its own brand IV-CEF in the parental dosage forms of 500 mg, 1gram and 2 grams.
"The launch of Cefpirome is a particular milestone in resolving complex chemistry by our in-house research and development (R&D), as the drug is the very first in the line of fourth generation treatment", said Lanka Srinivas, the director of the company.
There are just two players for the product in the entire globe, including Aventis which introduced it in 1986, Srinivas added.
Being one of the major players in the sterile cephalosporins, Aurobindo produces 29 bulk drugs in this segment.
One-fourth of its Rs 1,000 crore turnover comes from this segment. On the formulations front, Aurobindo has thus far launched 10 cephalosporin drugs and proposes to launch some more soon.
